The Challenge of sleeping sickness in sub-Saharan Africa

Lectures and events
Publication Date

James Black Prize Lecture

Video details

About 70 million people in sub-Saharan Africa are at risk of developing sleeping sickness, also called human African trypanosomiasis (HAT), and current treatments for the late, central nervous system (CNS) stage of the disease are fraught with difficulties – leading to death in almost 10% of cases treated with intravenous melarsoprol. However, untreated, or inadequately treated, sleeping sickness is almost always fatal.

Professor Peter Kennedy CBE FRSE explains how work being done in Glasgow has the potential to transform outcomes for people with this neglected tropical disease. He describes his work on an established mouse model of the disease, leading to a novel oral drug called ‘omplexed melarsoprol’, which has great promise for improving the lives of the rural poor.


Lecture report